For Clinics

The reference your practice needs to get CGRP prior authorizations right the first time.

CGRP therapies require prior authorization from 96% of managed care organizations. The average submission takes 15–45 minutes of staff time. Denial rates on first attempt run 20–40%.

96%
of payers require PA
15–45 min
staff time per submission
1,205
payers tracked
Free
no account required
Q1 2026 ActionsPayer Policy TablePA ToolEHR Smart PhrasesSubscribePolicy Watch
Looking for the full clinical briefing?Policy Pulse Q1 2026 — quarterly formulary and step therapy data for clinicians →
01

Q1 2026 Clinic Action Items

What changed this quarter and what your practice needs to do about it.

ACT

Botox PA: Domain-level MIDAS now required (Noridian)

Effective Feb 22, 2026, Noridian MAC requires documentation of all five MIDAS domains (A–E) individually at every Botox visit. A total score alone is no longer sufficient. Update your Botox visit note template immediately using the HV_Botox_LCD smart phrase below.

ACT

Audit concurrent CGRP + gepant prescriptions

Multiple payers have issued concurrent use policies restricting CGRP mAb + gepant preventive combinations. Review patients on both Qulipta (atogepant) and a CGRP mAb — most payers now require one to be discontinued or require separate PA approval for concurrent use.

California Medicaid: update step therapy documentation

Medi-Cal reduced CGRP mAb step therapy from 3 to 2 oral preventive failures (effective Feb 1, 2026). Update PA letters for California Medicaid patients — document 2 class failures, not 3.

Zavzpret: Cigna preferred tier, PA path simplified

Cigna moved zavegepant (Zavzpret) to preferred tier without a step therapy requirement. For Cigna patients with established migraine diagnosis, PA documentation no longer needs prior gepant trial history.

OptumRx/UHC: 12-month reauth for documented CGRP responders

Document ≥50% headache day reduction in your chart when submitting reauthorization. The reauth window is now 12 months — one well-documented renewal covers the full year.

Aetna MA: Vyepti now requires prior SC CGRP mAb trial

Aetna Medicare Advantage added step therapy before Vyepti (eptinezumab). Document erenumab or fremanezumab trial, or document clinical rationale for IV requirement (e.g., adherence to SC self-injection).

02

Payer Policy Quick Reference — Q1 2026

Key changes this quarter. Full dataset at Policy Pulse.

DrugPayerWhat changedWhat to doEffectiveImpact
Zavzpret (zavegepant)CignaAdded to preferred tier — no step therapy required for established migraine diagnosisSubmit PA without prior gepant trial documentation. Note: preferred tier status.Jan 1, 2026Favorable
Qulipta (atogepant)Medicaid (multiple states)Added to formulary in 14 additional state Medicaid programsVerify your state. Check step therapy requirements — most require one oral preventive failure.Jan–Mar 2026Favorable
CGRP mAbs (all)Medi-Cal (California)Step therapy requirements reduced from 3 to 2 oral preventive failuresUpdate PA documentation for California Medicaid patients — document 2 failures instead of 3.Feb 1, 2026Favorable
CGRP mAbs (all)OptumRx / UHCReauthorization interval extended from 6 months to 12 months for documented respondersDocument ≥50% headache day reduction at reauth. One renewal covers 12 months.Jan 1, 2026Favorable
Vyepti (eptinezumab)Aetna Medicare AdvantageStep therapy added: requires erenumab or fremanezumab trial before Vyepti approvalDocument subcutaneous CGRP mAb failure or IV requirement before submitting Vyepti PA.Jan 1, 2026Adverse
Botox (onabotulinumtoxinA)Noridian MAC (Medicare)Domain-level MIDAS documentation now required — total score alone no longer sufficientUse updated Botox smart phrase. Document all 5 MIDAS domains (A–E) individually at every visit.Feb 22, 2026Adverse

Full dataset (73,828 records, CC BY 4.0) at Policy Pulse and Research → Policy.

03

Prior Authorization Tool

Your clinician generates the letter. Here is what it needs to contain.

ELEMENT 1

Agent, dose, and route

Full medication name, dose, route (SC/IV), and frequency as the payer portal expects it.

ELEMENT 2

ICD-10 diagnosis code

G43.709 (chronic migraine w/o aura) or G43.719 (with aura). Episodic: G43.009. Must match the chart.

ELEMENT 3

Failed oral preventive trials

Drug class, specific agent, dose, duration, and reason for discontinuation — per payer requirements.

ELEMENT 4

Clinical rationale and functional impact

MIDAS grade, HIT-6 score, headache days/month. Quantified, not qualitative. "Frequent migraines" is not a PA narrative.

Generate a PA letter for your next patient

Free. No account required. Takes 3 minutes.

Open Prior Authorization Tool →
04

EHR Smart Phrase Downloads

Load into your EHR once. PA-ready documentation generates as a byproduct of routine charting.

Epic .smartphrase

Import via SmartPhrase Manager. Uses native Epic variables.

Athena .dotphrase

Import via Settings → Dot Phrases. Fill-in brackets notation.

eCW .txt

Copy-paste into Smart Text manager. Works in any EHR.

CGRP Preventive

PA documentation for CGRP monoclonal antibody preventive therapy. Includes diagnosis, failed trial documentation, functional impact, and medical necessity narrative.

Preview phrase.vaultcgrppa·A&P / Prior Authorization
DIAGNOSIS:
Primary: Chronic Migraine without aura, not intractable (G43.709)
Average headache days/month (past 3 months): [NUMBER] (threshold: ≥15)

REQUESTED MEDICATION: [CGRP AGENT, DOSE, ROUTE, FREQUENCY]
  Options: Erenumab (Aimovig) | Fremanezumab (Ajovy) | Galcanezumab (Emgality) | Eptinezumab (Vyepti)

MEDICAL NECESSITY:
- Chronic migraine confirmed (≥15 headache days/month ≥3 months)
- Functional impairment: MIDAS Grade [GRADE]; HIT-6 [SCORE]
- Failure of ≥2 oral preventive drug classes (documented below)

FAILED PREVENTIVE TRIALS:
1. [CLASS: e.g. Beta-blocker] — [Drug], [DOSE], [MONTHS] months — [Reason failed]
2. [CLASS: e.g. Tricyclic] — [Drug], [DOSE], [MONTHS] months — [Reason failed]
3. [CLASS: e.g. Anticonvulsant] — [Drug], [DOSE], [MONTHS] months — [Reason failed]

CURRENT ACUTE USE: [MEDICATIONS] — [DAYS] days/month — MOH: [YES/NO]

CLINICAL SUMMARY:
[PATIENT] is a [AGE]-year-old with chronic migraine (G43.709) who has failed [NUMBER]
oral preventive classes over [YEARS] years. Initiation of [AGENT] is medically necessary.

Botox / LCD DL39909

PA documentation for onabotulinumtoxinA for chronic migraine. Includes domain-level MIDAS fields required by Noridian MAC as of Feb 22, 2026.

Preview phrase.vaultbotox·A&P / Prior Authorization
DIAGNOSIS: Chronic Migraine (G43.709 / G43.719)
Headache days/month: [NUMBER] (≥15) | Migraine days/month: [NUMBER] (≥8)

MIDAS DOMAIN-LEVEL ASSESSMENT (required by Noridian MAC — Feb 22, 2026):
Domain A — Missed work/school days (past 3 months): [NUMBER]
Domain B — Days with reduced work/school productivity: [NUMBER]
Domain C — Missed household work days: [NUMBER]
Domain D — Days with reduced household productivity: [NUMBER]
Domain E — Missed family/social/leisure activity days: [NUMBER]
MIDAS Total: [SCORE] — Grade [I / II / III / IV]

LCD COMPLIANCE (DL39909):
[ ] ≥15 headache days/month for ≥3 months, ≥8 of which are migraine
[ ] ≥2 oral preventive drug class failures documented
[ ] MOH absent or managed | [ ] PREEMPT protocol

FAILED ORAL PREVENTIVES:
1. [Class]: [Drug], [DOSE], [MONTHS] months — [Reason failed]
2. [Class]: [Drug], [DOSE], [MONTHS] months — [Reason failed]

REQUESTED: OnabotulinumtoxinA [155–195] units per PREEMPT protocol, Q12W
Cycle #: [NUMBER] | Prior response: [≥50% reduction / partial / first cycle]

Acute Treatment Ladder

Step therapy documentation for acute PA: triptan trials, gepant rationale, ditan use, quantity limit attestation, and MOH screening.

Preview phrase.vaultacute·A&P / Prior Authorization
DIAGNOSIS: [G43.709 / G43.009 / G43.109]
CURRENT ACUTE USE: [MEDICATIONS] — [DAYS] days/month — MOH: [Not present / Present]

STEP THERAPY:
Step 1 — Triptan: [DRUG, DOSE, ROUTE] | Duration: [MONTHS] months
  Response: [Adequate / Inadequate] | Adverse effects: [None / Specify]

Step 2 — Second triptan (if Step 1 inadequate): [DRUG, DOSE, ROUTE]
  Response: [Adequate / Inadequate]

Step 3 — Gepant (if triptans failed or contraindicated):
  [Rimegepant 75mg / Ubrogepant 50mg or 100mg]
  Rationale: [Triptan contraindicated / Two failures / Intolerable side effects]

Step 4 — Ditan (if gepant also failed): Lasmiditan [dose]
  Rationale: [SPECIFY — CNS/driving warning documented]

QUANTITY LIMIT (if requesting above standard):
Attacks/month: [NUMBER] | Doses/attack: [NUMBER]
Clinical rationale: [BASIS FOR ABOVE-STANDARD QTY]

RESCUE: [Ondansetron / Prochlorperazine / Ketorolac / DHE / Other]

Specialist Referral

Neurology and headache specialist referral documentation with clinical summary, reason for referral, and specific questions for the specialist.

Preview phrase.vaultref·Plan / Referral
REFERRAL TO: [General Neurology / Headache Specialist / Specific provider: NAME]
DIAGNOSIS: [ICD-10: G43.709 / G43.009 / G43.719 / G44.009 / other]

REASON FOR REFERRAL:
[ ] Refractory chronic migraine — ≥3 failed preventive classes
[ ] CGRP mAb initiation/monitoring
[ ] Botox initiation (LCD DL39909)
[ ] PA appeal — specialist documentation requested
[ ] Other: [SPECIFY]

CLINICAL SUMMARY:
[PATIENT] is a [AGE]-year-old with [DURATION]-year history of [DIAGNOSIS].
Headache days/month: [NUMBER] | MIDAS Grade [GRADE] | HIT-6: [SCORE]
Failed preventives: [NUMBER classes] | Acute use: [DAYS] days/month
Imaging: [result or "None"] | Comorbidities: [LIST]

SPECIFIC QUESTIONS FOR SPECIALIST:
1. [QUESTION]
2. [QUESTION]

URGENCY: [Routine / Soon (4–6 wk) / Urgent]

After-Visit Summary: CGRP Preventive

Patient instructions for starting CGRP therapy. Includes months 1–3 timeline, reauth threshold, copay card section (delete for Medicare/Medicaid), and tracking instructions.

Preview phrase.vaultAVScgrp·After-Visit Summary
YOUR NEW MEDICATION:
[Aimovig / Ajovy / Emgality / Vyepti] — [DOSE] — [Monthly / Quarterly]
Given: [Self-inject at home / In clinic / Infusion center] | First dose: [DATE]

WHAT TO EXPECT:
Months 1–3: Most patients need 2–3 months to notice meaningful change.
  Keep using your acute medications as needed.
Month 3: Headache diary review determines reauthorization
  (goal: ≥50% reduction in headache days).
No response by month 3: We will discuss switching to a different CGRP agent.

TRACK EVERY DAY — including headache-free days.
Track at: headachevault.com / paper diary / Migraine Buddy

[DELETE FOR MEDICARE/MEDICAID — not applicable]
Copay assistance: Manufacturer cards available for commercial insurance.
[END DELETE]

CONTINUE YOUR ACUTE MEDICATION: [MEDICATION] as needed.
Alert: Contact us if using >10–15 days/month.

SIDE EFFECTS: Injection site reaction; constipation (Aimovig most common).
EMERGENCY: Hives, breathing difficulty → call 911.

After-Visit Summary: Botox Injection

Patient instructions after Botox injection. Includes 12-week cycle clock, 4-hour post-injection rules, payer stopping rule, and diary requirements.

Preview phrase.vaultAVSbotox·After-Visit Summary
WHAT HAPPENED: Botox injected at [NUMBER] sites (PREEMPT protocol) for chronic migraine.
How it works: Blocks neurotransmitters in migraine pathway. Effect builds gradually.

12-WEEK CYCLE: Next injection date: [DATE].
Do not miss — late injections affect insurance coverage.

NEXT 4 HOURS — RESTRICTIONS:
Do NOT: lie down | massage sites | exercise strenuously | apply heat

FIRST 2 WEEKS: Soreness and temporary headache worsening are normal (days 1–3).
Improvement builds from week 2.

INSURANCE STOPPING RULE: Requires ≥50% reduction in headache days by cycle 2–3.
Track every day — headachevault.com / paper diary / Migraine Buddy

ACUTE MEDS: Continue [MEDICATION] for breakthrough headaches.
SIDE EFFECTS: Bruising/soreness (resolves). Eyelid droop (rare, resolves).
EMERGENCY: Swallowing/breathing difficulty → call 911.

After-Visit Summary: Acute Medication Limits

Patient education on acute medication frequency limits and MOH risk. MOH section is clearly marked for deletion when not applicable.

Preview phrase.vaultAVSacute·After-Visit Summary
YOUR ACUTE MEDICATIONS:
[MEDICATION 1] — [DOSE] — take at first sign of migraine
[MEDICATION 2] — [DOSE] — [INSTRUCTIONS]
Rescue: [MEDICATION] — if primary fails

MONTHLY LIMITS:
[MEDICATION 1]: no more than [NUMBER] days/month
[MEDICATION 2]: no more than [NUMBER] days/month

[==== DELETE IF MOH NOT APPLICABLE ====]
⚠ MEDICATION OVERUSE HEADACHE (MOH):
Using triptans >10 days/month or analgesics/NSAIDs >15 days/month can cause
daily headaches (MOH). Signs: headaches >15 days/month, waking with headache,
medication working less well.
Your current use ([NUMBER] days/month) is [approaching / at] the threshold.
[==== END DELETE ====]

MONTHLY TARGET: ≤[NUMBER] days of acute medication use.
TRACK DAILY: headachevault.com / paper diary / Migraine Buddy

GO TO ED IF: Worst headache of life | Fever + stiff neck | Post-trauma |
New neuro symptoms | >72-hour attack

Patient Advocacy (HOH / HEADACHE Act)

PA appeal rights, step therapy override process, the HEADACHE Act (H.R. 5536), and Headache on the Hill resources for patients.

Preview phrase.vaultadvocacy·Patient Handout
YOUR RIGHTS WHEN A PA IS DENIED:

1. Right to appeal: First-level (internal) → second-level → external independent review.
   Do not accept denial without appealing.

2. Step therapy override: You may qualify if you previously failed required medications,
   they are contraindicated, or you are stable on a working medication.
   Our office can file the override request.

3. THE HEADACHE Act (H.R. 5536):
   Would set standards for PA decisions affecting headache patients.
   Contact your rep: house.gov/representatives/find
   Message: "I support the HEADACHE Act (H.R. 5536)."

HEADACHE ON THE HILL: Annual advocacy event — patients meet directly with Congress.
Learn more: allianceforheadacheadvocacy.org

APPEAL DOCUMENTATION WE WILL SUBMIT:
[ ] Clinical letter | [ ] MIDAS and HIT-6 scores | [ ] Headache diary data
[ ] Peer-reviewed evidence | [ ] Step therapy override request (if applicable)

RESOURCES: americanmigrainefoundation.org | allianceforheadacheadvocacy.org
PA Tool (free): headachevault.com/pa

Why Track Your Headaches

Patient logging instructions with 5-level functional impact scale and tool options. Positions Headache Vault first, with paper diary and Migraine Buddy as alternatives.

Preview phrase.vaultlogging·Patient Handout
WHY IT MATTERS: Your diary documents headache frequency (required by insurance
for CGRP/Botox), treatment response (≥50% reduction is the reauth threshold),
and MIDAS/functional impact for PA letters.

TRACK EVERY DAY — EVEN HEADACHE-FREE DAYS:
1. Headache? Yes / No
2. Severity: Mild (1–3) / Moderate (4–6) / Severe (7–10)
3. Functional impact:
   Level 1 — Minimal: normal activity
   Level 2 — Mild: most activities ok
   Level 3 — Moderate: difficulty with some activities
   Level 4 — Severe: must rest; many activities not possible
   Level 5 — Debilitating: bed rest; unable to function
4. Medication: which one(s) and how many doses
5. Triggers: sleep, stress, food, weather, hormones (optional)

HOW TO TRACK:
- Headache Vault (recommended): headachevault.com — free
- Paper diary: ask our office
- Migraine Buddy: export data and bring to appointments

BRING: 30 days of complete daily data to every appointment.

All templates released under CC BY 4.0. Download README for installation instructions and clinical citations.

05

What Changes When You Subscribe

Honest accounting of what the paid tier adds.

✓ Always Free

PA letter generation — unlimited, no account required
Payer policy reference — current quarter
Formulary tier lookup by drug and payer
EHR smart phrase downloads
Quarterly policy briefings (Policy Pulse)

Vault Specialist — $99/month

+PA history — letters saved to practice account
+Patient enrollment — 30-day headache tracking
+Vault Visit Report — functional summary for each patient, shareable with specialists
+Vault Payer Policy Update — Monday email when payer policies change in your state
+Medication complexity scoring — flags complex PA patients automatically
06

Vault Payer Policy Update

Monday morning email when payer policies change in your state. No account required.

Receive a short weekly digest when headache drug payer policies, formulary placements, or step therapy requirements change in your state. Plain language, clinic-ready.

07

Quarterly Policy Briefings

Prior releases — stable versioned URLs for citations and audits.

Q1 2026Policy Pulse — 1,204 payers, 73,828 records
2026-03-26

Start with the PA tool. It takes 3 minutes.

Free, no account required. Paste a clinical note or fill in the form — get a complete PA letter.

Open Prior Authorization Tool →See subscription pricing